Table 1.
Patient characteristics
| Number of patients | n = 125 |
|---|---|
| Median (range) age at diagnosis in years | 55 (28–85) |
| Performance status WHO: | |
| ▪ 0 | 15.2 % (19/125) |
| ▪ 1 | 77.6 % (97/125) |
| ▪ 2 | 7.2 % (9/125) |
| BSA (m2) | 1.69 (95 % CI; 1.65–1.72) |
| FIGO stage: | |
| ▪ I | 11.2 % (14/125) |
| ▪ II | 8.0 % (10/125) |
| ▪ IIIA | 5.6 % (7/125) |
| ▪ IIIB | 7.2 % (9/125) |
| ▪ IIIC | 56.0 % (70/125) |
| ▪ IV | 12.0 % (15/125) |
| Chemotherapy regimen: | |
| ▪ Paclitaxel/cisplatin | 43.2 % (54/125) |
| ▪ Paclitaxel/carboplatin/ caelyx | 8.8 % (11/125) |
| ▪ Paclitaxel/carboplatin | 36.8 % (46/125) |
| ▪ Carboplatin | 8.8 % (11/125) |
| ▪ Paclitaxel/carboplatin/epirubicin | 1.6 % (2/125) |
| ▪ Gemcitabine/ cisplatin | 0.8 % (1/125) |
| Type of histology: | |
| ▪ Serous | 54.4 % (68/125) |
| ▪ Endometrioid | 26.4 %(33/125) |
| ▪ Mucinous | 7.2 % (9/125) |
| ▪ Clear cell | 4.0 % (5/125) |
| ▪ Mixed | 2.4 % (3/125) |
| ▪ Unspecified | 5.6 % (7/125) |
| Grading: | |
| ▪ 1 | 3.2 % (4/125) |
| ▪ 2 | 32.8 % (41/125) |
| ▪ 3 | 23.2 % (29/125) |
| ▪ Unspecified | 40.8 % (51/125) |
| Primary surgery: | |
| ▪ Radical | 19.2 % (24/125) |
| ▪ Optimal (<1 cm) | 42.4 % (53/125) |
| ▪ Suboptimal (>1 cm) | 38.4 % (48/125) |